Breast Cancer Ireland recently announced new developments in the treatment of Triple Negative breast cancer. Glanbia is the headline sponsor of the charity’s flagship event, the Great Pink Run.
As a result of our partnership, Breast Cancer Ireland has spearheaded a number of research initiatives, including the funding of new research into Triple Negative Breast Cancer led by Dr Paul Mullan, from the Patrick G. Johnston Centre for Cancer Research at Queens University Belfast.
This research, which commenced in October 2018, is now showing promising results in the fight against the growth and spread of the most aggressive Triple Negative Breast Cancers (TNBCs). Aisling Hurley CEO of Breast Cancer Ireland thanked Glanbia employees for their support for the breast cancer cause every year through fundraising activities and their involvement in the Great Pink Run.
“Glanbia’s support has made a massive difference in our race for a cure. We have been investing hugely in triple negative breast cancer through our efforts with Queens University in Belfast and their efforts to identify new, targeted therapies for those that are diagnosed. We are also investing in research into metastatic disease. It is very much down to the support you have given us through your own initiatives and also your support of our annual Great Pink Run annually.
1.7 million women worldwide face a diagnosis of breast cancer each year. Around 1 in 8 women in the US (about 12%) will develop invasive breast cancer over the course of their lifetime. However, data shows that survival rates are improving year on year, currently standing at 85% with mortality rates reducing by 2% each year, and importantly, local control of breast cancer is improving year on year.
The Great Pink Run with Glanbia raised in excess of €930,000 for breast cancer research in 2020. The event went virtual and global for the first time ever, with 15,000 global participants clocking up 65,208 km in total.